The quest to improve MDMA
Business Trip, a podcast about the business of psychedelics
Welcome back to Business Trip, a podcast about the business of psychedelics! 🍄
This episode shares the story of Tactogen, a drug development company making new chemical entities inspired by MDMA. Co-founder Matt Baggott has been fascinated by MDMA and has studied it for 30 years. And while he believes that MDMA can be effective as a therapeutic, his company is developing an MDMA analogue that is designed to be gentler and safer, with the potential to be administered in an at-home setting.
In this episode, we discuss:
Matt’s insights around MDMA that led to founding Tactogen
The process of designing a new chemical entity
Whether MDMA is really a psychedelic
Tactogen’s community stakeholder initiative
Listen to the episode here, on Spotify or Apple Podcasts.
When you’re done listening, tweet at us @businesstripfm to share your thoughts!
About Us
Business Trip is a podcast about psychedelic startups. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re partners at PsyMed Ventures, advocates of the healing powers of psychedelic medicine.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?
Follow us on Twitter & Instagram.
So what does it take to design this new chemical entity and ultimately receive FDA approval? Matt shares Tactogen's vision to develop the next blockbuster drug.